$0.94
6.14% yesterday
Nasdaq, Nov 15, 10:12 pm CET
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Ocugen Inc Stock price

$0.94
-0.01 0.90% 1M
-1.02 52.11% 6M
+0.36 63.23% YTD
+0.56 147.26% 1Y
-7.36 88.69% 3Y
+0.38 67.76% 5Y
-704.06 99.87% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.06 6.14%
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Key metrics

Market capitalization $270.18m
Enterprise Value $238.26m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 50.69
P/S ratio (TTM) P/S ratio 57.49
P/B ratio (TTM) P/B ratio 6.71
Revenue (TTM) Revenue $4.70m
EBIT (operating result TTM) EBIT $-52.44m
Cash position $38.70m
EPS (TTM) EPS $-0.18
P/E forward negative
P/S forward 79.46
EV/Sales forward 77.02
Short interest 18.35%
Show more

Is Ocugen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Ocugen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

Buy
100%

Financial data from Ocugen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4.70 4.70
-
100%
- Direct Costs - -
-
-
3.15 3.15
389% 389%
67%
- Selling and Administrative Expenses 23 23
26% 26%
494%
- Research and Development Expense 31 31
34% 34%
669%
- -
-
-
- Depreciation and Amortization 1.55 1.55
42% 42%
33%
EBIT (Operating Income) EBIT -52 -52
35% 35%
-1,116%
Net Profit -51 -51
32% 32%
-1,088%

In millions USD.

Don't miss a Thing! We will send you all news about Ocugen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocugen Inc Stock News

Neutral
Seeking Alpha
7 days ago
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
8 days ago
Subsequent to quarter-end, closed $30 million in debt financing OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025 OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical tria...
Neutral
GlobeNewsWire
9 days ago
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that on November 6, 2024, the Company entered into a new $30 million credit facility with Avenue Venture Opportunities Fund, L.P., a fund of Ave...
More Ocugen Inc News

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Head office United States
CEO Shankar Musunuri
Employees 65
Founded 2013
Website www.ocugen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today